SEC Form 4 · accession 0001209191-17-017485
Corbus Pharmaceuticals Holdings, Inc. · CRBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean F. Moran
Officer — Chief Financial Officer
Period of report
Mar 1, 2017
Accepted (ET)
Mar 3, 2017 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001595097
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option(right to buy)F1 | $9.05 | Mar 1, 2017 | A | 115,000 | A | — | Mar 1, 2027 | Common Stock | 115,000 | 115,000 | D |
Explanation of responses
- F1The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 1, 2018, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018.